121443-79-6

Basic information

• Product Name: Benzenemethanamine, 2,6-dichloro-a-methyl-,(S)-
• Synonyms: Benzenemethanamine, 2,6-dichloro-a-methyl-,(S)-;Benzenemethanamine, 2,6-dichloro-α-methyl-, (S)- (9CI);6-dichloro-a-Methyl-;(S)-1-(2,6-DICHLOROPHENYL)ETHANAMINE-HCl;(S)-1-(2,6-Dichlorophenyl)ethanaMine hydrochloride;(S)-2,6-DICHLORO-ALPHA-METHYL-BENZENEMETHANAMINE;(1S)-1-(2,6-dichlorophenyl)ethanamine,hydrochloride;(S)- 2,6-dichloro-a-methyl-Benzenemethanamine
• CAS NO: 121443-79-6
• Molecular Formula: C₈H₉Cl₂N
• Molecular Weight: 190.07216
• Product Categories: API intermediates
• Mol File: 121443-79-6.mol

Chemical Properties

• Boiling Point: 248.142 °C at 760 mmHg
• Flash Point: 103.873 °C
• Appearance: /
• Density: 1.262 g/cm³
• PKA: 7.96±0.10(Predicted)
• CAS DataBase Reference: Benzenemethanamine, 2,6-dichloro-a-methyl-,(S)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenemethanamine, 2,6-dichloro-a-methyl-,(S)-(121443-79-6)
• EPA Substance Registry System: Benzenemethanamine, 2,6-dichloro-a-methyl-,(S)-(121443-79-6)

Safety Data

• Hazardous Substances Data: 121443-79-6(Hazardous Substances Data)

Usage

Uses

Used in Chemical Synthesis:
Benzenemethanamine, 2,6-dichloro-a-methyl-,(S)is used as an intermediate in the synthesis of other organic compounds. Its unique structure and functional groups make it a valuable building block for creating a wide range of chemical products.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, Benzenemethanamine, 2,6-dichloro-a-methyl-,(S)is utilized as a chiral building block. Its stereochemistry plays a vital role in the development of enantiomerically pure drugs, which can exhibit different biological activities and reduce potential side effects.
Used in Agrochemicals:
Benzenemethanamine, 2,6-dichloro-a-methyl-,(S)is also employed in the agrochemical sector as a chiral building block for the synthesis of enantiomerically pure pesticides and other agrochemicals. This ensures the desired biological activity while minimizing environmental impact.
Overall, the specific properties and uses of Benzenemethanamine, 2,6-dichloro-a-methyl-,(S)may vary depending on the intended application and the methods used for its production and modification. Its versatility in chemical synthesis and its importance in the pharmaceutical and agrochemical industries highlight its significance as a valuable chemical compound.

Upstream product

• 121443-78-5 (1S)-N-Trimethylsilyl-1-(2-chlorophenyl)ethylamine 
• 121443-77-4 N-<(S)-1-phenylethyl>(trimethylsilyl)amine 
• 68285-26-7 (S)-α-(o-chlorophenyl)ethylamine 
• 2627-86-3 (S)-1-phenyl-ethylamine 

Downstream Products

• 126017-63-8 4-[1-(2,6-Dichloro-phenyl)-ethylcarbamoyl]-butyric acid 
• 121443-81-0 (S)-N-<1-(2,6-Dichlorophenyl)ethyl>-2-(3,4-dimethoxyphenyl)acetamide 
• 121443-83-2 (S)-N-<2-(3,4-Dimethoxyphenyl)ethyl>-1-(2,6-dichlorophenyl)ethylamine 
• 121443-88-7 (S)-N-<1-(2,6-Dichlorophenyl)ethyl>-N-<2-(3,4-dimethoxyphenyl)ethyl>acetamide 
• 121443-89-8 (S)-N-<1-(2,6-Dichlorophenyl)ethyl>-N-<2-(3,4-dimethoxyphenyl)ethyl>propanamide 
• 121443-90-1 (S)-N-<1-(2,6-Dichlorophenyl)ethyl>-N-<2-(3,4-dimethoxyphenyl)ethyl>-2-methylpropanamide 
• 121443-91-2 (S)-N-<1-(2,6-Dichlorophenyl)ethyl>-N-<2-(3,4-dimethoxyphenyl)ethyl>(3,4-dimethoxyphenyl)acetamide 
• 126017-89-8 5-Allyl-1-[(S)-1-(2,6-dichloro-phenyl)-ethyl]-pyrrolidin-2-one 
• 126017-80-9 1-[(S)-1-(2,6-Dichloro-phenyl)-ethyl]-5-hydroxy-pyrrolidin-2-one 
• 126035-17-4 1-<(1S)-1-(2,6-Dichlorophenyl)ethyl>glutarimide 
• 126035-20-9 1-<(1S)-1-(2,6-Dichlorophenyl)ethyl>-6-hydroxy-2-piperidinone 
• 126017-65-0 6-Allyl-1-[(S)-1-(2,6-dichloro-phenyl)-ethyl]-piperidin-2-one 
• 126017-65-0 (6R)-(+)-1-<(1S)-1-(2,6-Dichlorophenyl)ethyl>-6-(1-prop-2-enyl)-2-piperidinone 

Relevant articles and documents

N-BIPHENYLMETHYLINDOLE MODULATORS OF PPARG

The invention provides molecular entities that bind with high affinity to PPARG (PPAR3), inhibit kinase-mediated, e.g., cdk5-mediated, phosphorylation of PPARG, but do not exert an agonistic effect on PPARG. Compounds of the invention can be used for treatment of conditions in patients wherein PPARG plays a role, such as diabetes, insulin resistance, impaired glucose tolerance, pre-diabetes, hyperglycemia, hyperinsulinemia, obesity, or inflammation. In methods of treatment of these conditions using a compound of the invention, the compound can avoid producing side effects of significant weight gain, edema, impairment of bone growth or formation, or cardiac hypertrophy, or any combination thereof, in the patient receiving the compound. Methods of preparation of the compounds, bioassay methods for evaluating compounds of the invention as non-agonistic PPARG binding compounds, and pharmaceutical compositions are also provided.

An efficient preparation of (S)-(-)-1-(2,6-dichlorophenyl)ethylamine

(S)-(-)-1-(2,6-Dichlorophenyl)ethylamine has been prepared from (S)-α-phenethylamine in 2 steps in 44% overall yield.

Stereoselective Nucleophilic Additions to the Carbon-Nitrogen Double Bond. 2. Chiral Iminium Ions Derived from "Second Generation" Chiral Amines

"Second generation" chiral amines (1S)-(-)-1-(2-chlorophenyl)ethylamine (4) and (1S)-(-)-1-(2,6-dichlorophenyl)ethylamine (5) have been prepared from commercially available (S)-(-)-α-phenethylamine.These chiral reagents have been incorporated into chiral